Food:
I continue to hold COR because you never know. Little biotechs can pull a rabbit out of their hats once in a while. But I wouldn't buy anymore of it. That's just my take. In my 40's I took bigger risks, hence my addiction to upstart biotechs. I only hold 4 of them now. COR, which has been my worst performer. CVM, which is in a tight (low) trading range. AVII, which has promise and has shown some nice relative strength lately. And last but not least, PPHM, which had a huge run-up today (much to my delight). I'll hold PPHM for sure. They have too many good things going on at the moment, with anti-viral and anti-cancer platforms aand an upcoming presentation at ASCO. I'll take a wait and see approach to AVII. If their collaboration with Cook Medical pans out for a new version of a drug coated cardiac stent then I'll hang on. I've run out of patience with COR and will dump it by year end if it hasn't made progress. I don't own all that much CVM, so it's an afterthought for me. I switched over to ETF's last year. I like the way you can have diversification among companies in an industry or sector you find favorable and you can trade them in real time. I still own a few individual issues, like Petrobras (PBR) and NVDA and Hecla Mining (HL). But the majority of my portfolio is now in ETF's.
And while I have losses in COR, I wouldn't say I was suckered into buying it. They had real prospects. I think the FDA rejection on the basis of histological artifact from the slide mounting process was a combination of COR's bad luck and the FDA's incompetence and bias against neuro drugs. That cost them millions of dollars and years of work and severly set the company back. I don't think they ever really recovered from that. You win some, you lose some. All is not lost (yet). But after all this frustration and dilution after dilution...it will soon be time for me to close the book on this one. No regrets. You can't win them all.
News 
Market Data 
Discover 
AI
